PANDAS/PANS is a clinically distinct entity and needs early and prompt immunotherapy Host: Alicja Kalinowska, Poland Yes: Ronny Wickström, Sweden No: Ming Lim, UK Treatment of CIDP – immunoglobulins or steroids first?
Host: Joab Chapman, Israel Immunoglobulins: Marinos Dalakas, USA Steroids: Eduardo Nobile-Orazio, Italy New regulatory-approved medications should be used exclusively for prevention of attacks of NMOSD over (currently used) non-regulatory approved medications
Host: Brian Weinshenker, USA NMOSD attacks should be treated with apheresis/plasma exchange at first presentation, either with or without corticosteroids
Host: Bruno Gran, UK Yes: Ingo Kleiter, Germany No: M Isabel Leite, UK 2015 International Panel criteria for NMOSD are outdated and should be replaced with a diagnostic classification primarily based on autoantibody status rather than clinical presentation (e.g. AQP4 disease, MOG disease)
Capsule: We now know the molecular target of the autoimmune insult in the majority of patients with NMOSD, and we can use a molecular classification based on the target of the antibody in lieu of clinical criteria for diagnosis of what we currently refer to as NMOSD. Some would argue “not so fast.” Are we ready for a molecular classification of NMOSD in 2020? Yes: Angela Vincent, UK No: Ingo Kleiter, Germany Is narcolepsy an autoimmune disorder which should be treated as such?